Hansa Biopharma at a glance

Hansa Biopharma is leveraging its proprietary immunomodulatory enzyme technology platform to develop treatments for rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection and cancer.

The Company’s lead product candidate, imlifidase, is an antibody-degrading enzyme being developed to enable kidney transplantation in highly sensitized patients and may be further developed for use in other solid organ transplantation and acute autoimmune indications. Imlifidase is currently under review for a potential marketing authorization by European Medicines Agency (EMA).

Hansa’s research and development program is advancing the next generation of the Company’s enzyme technology to develop novel IgG-cleaving enzymes with lower immunogenicity, suitable for repeat dosing in relapsing autoimmune diseases and oncology. Hansa Biopharma is based in Lund, Sweden and also has operations in other European countries and in the US.

Our Equity Story

Imlifidase works
Imlifidase cleaves IgG antibodies

Imlifidase is a unique IgG antibody-cleaving enzyme studied in five clinical studies. By removing the immunological barrier, imlifidase has the potential to enable kidney transplantation in highly sensitized patients.

Addresses a clear unmet need
Potentially addressing a clear unmet need

Patients may become sensitized after losing a first transplant or being exposed to foreign tissues through blood transfusion or pregnancy. Such sensitized patients account for roughly 30% of people on the kidney waiting lists.

Well positioned for commercial success
A company well positioned for commercial success

Hansa Biopharma is establishing its own commercial and medical organization in EU and the US. Outside these core markets we will seek commercial partnerships. Hansa Biopharma has a broad patent coverage throughout 2035 in key markets and orphan drug designation in EU and US for imlifidase in kidney transplantation.

Rich pipeline
Rich pipeline

We are leveraging our proprietary immunomodulatory enzyme platform in phase 2 clinical studies in rare autoimmune indications including anti-GBM (Goodpasture’s disease), Guillain-Barré syndrome and acute Antibody Mediated Rejection (AMR) post transplantation, all with Orphan Drug status.

Learn More

Latest Financial Results

View All Results
View all news

Latest News

View all events

Upcomming Events

Milestones and near-term news flow

Near Term News Near Term News

For any investor related inquiries, please contact IR@hansabiopharma.com